Featured:
The PRINCIPLE Trial - two years on
16 May 2022
The PRINCIPLE Trial has led the way in evaluating treatments for COVID-19 in the community over the last two years.
10,000 people join the PRINCIPLE Trial – A huge ‘Thank You’ from us all.
31 March 2022
10,000 people have joined the PRINCIPLE Trial over the last two years and we want to say a big ‘Thank You’ to them all for their amazing contribution to testing treatments for COVID-19 in the community.
Latest research news and updates
Reflecting on PANORAMIC and PRINCIPLE, three years into the COVID-19 Pandemic
30 March 2023
Earlier this month—Saturday 11 March 2023—we marked the third anniversary of the World Health Organization (WHO) declaring the COVID-19 pandemic. This anniversary is an opportunity to reflect on the lessons learned from the pandemic and renew efforts to strengthen health systems and ensure equitable access to vaccines and treatments.
Largest Hindu temple in Europe opens new health hub whilst providing continued support for PANORAMIC and PRINCIPLE trials
5 September 2022
Europe’s BAPS Swaminarayan Sanstha, with the Neasden Temple, one of the largest Hindu temples outside of India, has opened a new community health hub in west London. Following their continued support of the PANORAMIC and PRINCIPLE trials, the temple’s interactive health hub will engage visitors around health awareness and wellbeing.
Findings into colchicine published in the British Journal of General Practice
19 April 2022
Findings from research by the PRINCIPLE Trial into treatment of COVID-19 in the community with the anti-inflammatory drug colchicine published in the British Journal of General Practice.
PRINCIPLE trial 'highly commended' for innovative use of health data
5 July 2021
The PRINCIPLE trial has been highly commended at the Health Data Research UK Awards for the way in which patient data is utilised so participants are contacted about the trial soon after receiving a positive test result.
Ivermectin to be investigated in adults aged 18+ as a possible treatment for COVID-19 in the PRINCIPLE trial
23 June 2021
From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.
Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19
12 April 2021
Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants. The drug is now available to treat COVID-19 on a case-by-case basis in UK primary care.
Favipiravir to be investigated as a possible COVID-19 treatment for at-home recovery in the PRINCIPLE trial
8 April 2021
Could the antiviral favipiravir help transform COVID-19 into an illness that can be successfully treated by general practitioners?
PRINCIPLE COVID-19 treatments trial widens to under 50s and adds colchicine
3 March 2021
From today, the UK’s national priority platform trial of COVID-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.
Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial
25 January 2021
Update from the Chief Investigators of the Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE), 25 January 2021
De Montford University Leicester students to support PRINCIPLE trial recruitment
20 January 2021
Students from De Montfort University Leicester (DMU) are the first in the country to help drive the PRINCIPLE clinical study to find Covid-19 treatments for the over 50’s that can help speed up recovery.
Inhaled corticosteroids to be investigated as a possible treatment for Covid-19 in national PRINCIPLE Trial
27 November 2020
Inhaled budesonide is an inexpensive, safe and commonly prescribed treatment for asthma and COPD. It is the fourth medication to be tested in PRINCIPLE.
Two major pharmacy chains join PRINCIPLE Trial
18 November 2020
Two of the UK’s largest pharmacy chains, LloydsPharmacy and Well Pharmacy, are tasking their branches with helping to find suitable patients for the PRINCIPLE Trial of Covid-19 treatments.
Britain’s most influential Hindu temple spreads awareness of the PRINCIPLE trial among Indian community
21 October 2020
Europe’s BAPS Swaminarayan Sanstha, the largest Hindu temple outside of India, is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.
PRINCIPLE Trial of COVID-19 treatments recruits 1000th participant
1 October 2020
More than 1000 people across the UK have signed-up to take part in the UK-wide PRINCIPLE Trial of potential community-based treatments for COVID-19, led by Oxford University.
PRINCIPLE Trial to strengthen Black, Asian and minority ethnic community participation
18 September 2020
Professor Mahendra G Patel, University of Bradford, joins PRINCIPLE Trial as National Black, Asian and minority ethnic Community and Pharmacy Lead
PRINCIPLE and ZOE partner to widen access to trial
3 August 2020
Oxford University and the COVID Symptom Study app are joining forces to widen access to the PRINCIPLE trial of potential treatments for COVID-19.
PRINCIPLE Trial calls on UK primary care to support patient recruitment
22 June 2020
The Co-Chief Investigators of the PRINCIPLE Trial, Professor Chris Butler and Professor Richard Hobbs, write an open letter to health professionals across UK primary care calling on their support, so those who are still contracting COVID-19 are given the opportunity to join the trial.
National priority COVID-19 trial recruits first patients
17 April 2020
Researchers from Oxford University are now enrolling participants into PRINCIPLE, the first clinical trial of potential COVID-19 treatments to take place in GP practices.